American Regent vs. Long Grove: Selenium Patent Suit Ends in Swift Voluntary Dismissal in Delaware
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | American Regent, Inc. v. Long Grove Pharmaceuticals, LLC |
| Numéro de dossier | 1:24-cv-00825 (D. Del.) |
| Tribunal | Tribunal fédéral de première instance pour le district du Delaware |
| Durée | July 16, 2024 – August 19, 2024 34 days |
| Résultat | Retrait volontaire de la plainte par le demandeur (sans préjudice) |
| Brevets en cause | |
| Produits incriminés | Long Grove Selenious Acid Formulations (Eq. 600 mcg, 60 mcg, 12 mcg Selenium) |
Aperçu du dossier
Les parties
⚖️ Demandeur
New York-based specialty pharmaceutical company and a subsidiary of Luitpold Pharmaceuticals. American Regent has a well-established portfolio of injectable pharmaceutical products, including micronutrient formulations used in parenteral nutrition.
🛡️ Défendeur
Pharmaceutical company offering competing selenium formulations. Its accused products directly mirror the concentration profiles of American Regent’s products, suggesting Long Grove entered the market with a parallel product line targeting the same clinical applications.
Le brevet en cause
This case involved U.S. Patent No. US11998565B2 (Application No. US18/124391), covering selenious acid formulations for parenteral selenium supplementation. Selenious acid is a critical trace element administered intravenously to patients receiving total parenteral nutrition (TPN). The patent’s claims likely cover specific concentration thresholds, formulation parameters, or manufacturing processes that distinguish the covered products from prior art alternatives.
- • US11998565B2 — Selenious acid formulations for intravenous selenium supplementation.
Vous développez un produit pharmaceutique similaire ?
Check if your formulation might infringe this or related patents before launch.
Le verdict et l'analyse juridique
Résultat
The case was terminated by voluntary dismissal without prejudice pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i). No damages were awarded. No injunctive relief was granted or denied. No judicial ruling on the merits was issued. Because the dismissal was without prejudice, American Regent retains the right to refile the same claims against Long Grove in a future action, subject to applicable statutes of limitations and any procedural constraints.
Note: Specific settlement terms, licensing agreements, or underlying commercial arrangements, if any, were not disclosed in the public record.
Principales questions juridiques
The strategic calculus behind a Rule 41(a)(1)(A)(i) dismissal at this juncture is instructive. This mechanism is only available prior to the defendant’s answer or summary judgment motion — meaning American Regent acted swiftly and deliberately. Possible explanations include:
- Out-of-court resolution: Parties may have reached a licensing agreement or consent arrangement off the docket.
- Patent prosecution development: Activity on Application No. US18/124391 may have warranted reassessment of claim scope before proceeding.
- Tactical repositioning: Plaintiff may have identified a stronger legal theory, additional patents, or preferred venue for a subsequent action.
- Commercial negotiation: A business resolution may have rendered continued litigation unnecessary.
While this case produced no precedential ruling, it highlights the increasing use of voluntary dismissal as a strategic tool in ANDA-adjacent pharmaceutical patent litigation.
Freedom to Operate (FTO) Analysis for Pharmaceutical Formulations
Ce cas met en évidence les risques critiques liés à la propriété intellectuelle dans la conception de formulations pharmaceutiques spécialisées. Choisissez la prochaine étape :
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige pharmaceutique.
- View all related patents in the selenious acid technology space
- Découvrez quelles sont les entreprises les plus actives dans le domaine des brevets liés à la nutrition parentérale
- Comprendre les schémas d'interprétation des revendications pour des formulations similaires
🔍 Vérifier les risques liés à mon produit
Réalisez une analyse FTO complète pour votre propre technologie ou produit pharmaceutique.
- Input your product description or technical formulation features
- AI identifies potentially blocking patents in clinical nutrition
- Get actionable risk assessment report for your IP team
Zone à haut risque
Identical selenious acid concentration profiles
1 Brevet clé
US11998565B2 at issue
Options de contournement
Potential for formulation tweaks
✅ Points clés à retenir
Rule 41(a)(1)(A)(i) voluntary dismissal without prejudice is a tactically viable tool when litigation timing requires adjustment post-filing.
Rechercher la jurisprudence connexe →A complaint filed and voluntarily dismissed without prejudice can serve legitimate strategic purposes, including signaling enforcement intent or initiating licensing discussions.
Explorer les stratégies contentieuses →Foire aux questions
The case involved U.S. Patent No. US11998565B2 (Application No. US18/124391), covering selenious acid formulations used for intravenous selenium supplementation.
American Regent voluntarily dismissed all claims without prejudice under Fed. R. Civ. P. 41(a)(1)(A)(i) after 34 days. No public explanation was provided; potential reasons include out-of-court resolution, licensing negotiations, or strategic repositioning.
Yes. A without-prejudice dismissal preserves American Regent’s right to refile the same claims against Long Grove, subject to applicable statutes of limitations.
A ‘without prejudice’ dismissal allows the plaintiff to refile the lawsuit later. In pharma patent litigation, this can be a strategic move to re-evaluate claims, pursue licensing, or consolidate litigation efforts, offering flexibility without conceding on the merits.
Prêt à renforcer votre stratégie en matière de brevets pharmaceutiques ?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision in the pharma sector.
Références
- PACER — Case No. 1:24-cv-00825, D. Del.
- USPTO Patent Center — US11998565B2
- Cornell Legal Information Institute — Fed. R. Civ. P. 41
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.